Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07685470 Gemcitabine Hydrochloride Advanced Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07685470 clinical trial report covering Gemcitabine Hydrochloride, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07683949 Lenvatinib mesylate Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07683949 clinical trial report covering Lenvatinib mesylate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07687212 Henagliflozein Proline Heart failure with normal ejection fraction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07687212 clinical trial report covering Henagliflozein Proline, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07683403 Cetuximab RAS/BRAF Wild Type Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07683403 clinical trial report covering Cetuximab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07688096 Doxycycline Hyclate Joint Laxity, Familial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07688096 clinical trial report covering Doxycycline Hyclate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07682870 VG2062 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07682870 clinical trial report covering VG2062, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07688577 XTX-501 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07688577 clinical trial report covering XTX-501, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260289 ONO-4538HSC Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
JPRN-jRCT2031260289 clinical trial report covering ONO-4538HSC, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07686068 VBC106 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07686068 clinical trial report covering VBC106, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07688148 TAX-2 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07688148 clinical trial report covering TAX-2, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07692750 IBI-343 Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07692750 clinical trial report covering IBI-343, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07696377 Obinutuzumab β Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07696377 clinical trial report covering Obinutuzumab β, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.